Pneumologie 2022; 76(S 01): S49-S50
DOI: 10.1055/s-0042-1747800
DOI: 10.1055/s-0042-1747800
Abstracts
Durvalumab+ Tremelimumab + Platin-Etoposide in first-line extensive-stage SCLC (ES-SCLC): 36-month Overall Survival from the Phase 3 CASPIAN study
Authors
-
H Bischoff
1 Thoraxklinik -
L Paz-Ares
2 Hospital Universitario 12 de Octobre -
Y Chen
3 Cancer & Hematology Centers of Western Michigan -
N Reinmuth
4 Asklepios Lung Clinic -
K Hotta
5 5okayama University Hospital -
D Trukhin
6 Odesa Regional Oncological Dispensary -
G Statsenko
7 Omsk Regional Cancer Center -
M J Hochmair
8 Karl Landsteiner Institute of Lung Research and Pulmonary Oncology -
M Özgüroğlu
9 9istanbul University−cerrahpaşa -
J H Li
10 Samsung Changwon Hospital -
O Voitko
11 Kyiv City Clinical Oncological Centre -
A Poltoratskiy
12 Petrov Research Institute of Oncology -
F Verderame
13 Ao Ospedali Riuniti Po Vincenzo Cervello -
L Havel
14 Thomayer Hospital -
I Bondarenko
15 Dnipropetrovsk Medical Academy -
G Losonczy
16 Semmelweis University -
N Conev
17 Medical Oncology -
H Broadhurst
18 Plus-Project Ltd -
T Dalvi
19 Astrazeneca -
H Jiang
19 Astrazeneca -
J W Golgman
20 David Geffen School of Medicine at Ucla -
J Alt
21 University Medical Center Mainz
